HRP20251312T1 - Poboljšana protutijela za il-6 - Google Patents
Poboljšana protutijela za il-6Info
- Publication number
- HRP20251312T1 HRP20251312T1 HRP20251312TT HRP20251312T HRP20251312T1 HR P20251312 T1 HRP20251312 T1 HR P20251312T1 HR P20251312T T HRP20251312T T HR P20251312TT HR P20251312 T HRP20251312 T HR P20251312T HR P20251312 T1 HRP20251312 T1 HR P20251312T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- image
- antibody
- heavy chain
- light chain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077105P | 2014-11-07 | 2014-11-07 | |
| US201462087448P | 2014-12-04 | 2014-12-04 | |
| US201562247705P | 2015-10-28 | 2015-10-28 | |
| EP23189385.0A EP4268843B1 (en) | 2014-11-07 | 2015-11-06 | Improved il-6 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20251312T1 true HRP20251312T1 (hr) | 2025-12-05 |
Family
ID=54602042
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20251312TT HRP20251312T1 (hr) | 2014-11-07 | 2015-11-06 | Poboljšana protutijela za il-6 |
| HRP20191945TT HRP20191945T1 (hr) | 2014-11-07 | 2015-11-06 | Poboljšana il-6-protutijela |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191945TT HRP20191945T1 (hr) | 2014-11-07 | 2015-11-06 | Poboljšana il-6-protutijela |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US11142571B2 (OSRAM) |
| EP (3) | EP3632931A1 (OSRAM) |
| JP (1) | JP6594438B2 (OSRAM) |
| KR (2) | KR102770849B1 (OSRAM) |
| CN (1) | CN107249631B (OSRAM) |
| AU (1) | AU2015342882B2 (OSRAM) |
| CA (1) | CA2965689C (OSRAM) |
| CL (1) | CL2017001135A1 (OSRAM) |
| CO (1) | CO2017005404A2 (OSRAM) |
| CR (1) | CR20170231A (OSRAM) |
| DK (2) | DK3215530T3 (OSRAM) |
| EA (1) | EA035199B1 (OSRAM) |
| ES (1) | ES2756275T3 (OSRAM) |
| FI (1) | FI4268843T3 (OSRAM) |
| HR (2) | HRP20251312T1 (OSRAM) |
| HU (1) | HUE046181T2 (OSRAM) |
| IL (1) | IL251858B (OSRAM) |
| LT (1) | LT4268843T (OSRAM) |
| MA (1) | MA51554A (OSRAM) |
| MX (2) | MX385206B (OSRAM) |
| MY (1) | MY185114A (OSRAM) |
| PE (1) | PE20171107A1 (OSRAM) |
| PH (1) | PH12017500809B1 (OSRAM) |
| PL (2) | PL3215530T3 (OSRAM) |
| PT (2) | PT3215530T (OSRAM) |
| RS (2) | RS67353B1 (OSRAM) |
| SA (1) | SA517381458B1 (OSRAM) |
| SG (2) | SG11201703574VA (OSRAM) |
| SI (1) | SI3215530T1 (OSRAM) |
| UA (1) | UA122673C2 (OSRAM) |
| WO (1) | WO2016073890A1 (OSRAM) |
| ZA (1) | ZA201702985B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102725051B1 (ko) | 2015-09-23 | 2024-11-04 | 제넨테크, 인크. | 항-vegf 항체의 최적화된 변이체들 |
| CN108718522A (zh) * | 2016-02-23 | 2018-10-30 | 赛森生物股份有限公司 | Il-6拮抗剂制剂及其用途 |
| CA3047059A1 (en) * | 2016-12-19 | 2018-06-28 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
| AR111249A1 (es) | 2017-03-22 | 2019-06-19 | Genentech Inc | Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares |
| JP7216006B2 (ja) | 2017-03-22 | 2023-01-31 | ジェネンテック， インコーポレイテッド | ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法 |
| CN109867723B (zh) * | 2017-12-05 | 2022-06-17 | 南京金斯瑞生物科技有限公司 | 抗人il6单克隆抗体及其制备方法和用途 |
| EP4118114A1 (en) | 2020-03-13 | 2023-01-18 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| PE20230414A1 (es) | 2020-03-24 | 2023-03-07 | Genentech Inc | Agentes de fijacion a tie2 y metodos de uso |
| AU2021360935A1 (en) | 2020-10-15 | 2023-05-25 | F. Hoffmann-La Roche Ag | Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics |
| CN116355825A (zh) * | 2022-02-25 | 2023-06-30 | 南京工业大学 | 一种强化纤维素合成来提高人表皮生长因子分泌生产效率的方法 |
| CN115343483B (zh) * | 2022-08-12 | 2024-11-26 | 苏州邦器生物技术有限公司 | 一种自身免疫性糖尿病检测用试剂盒及其制备方法 |
| AU2023369998A1 (en) * | 2022-10-24 | 2025-01-23 | F. Hoffmann-La Roche Ag | Predicting response to il-6 antagonists |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| EP1471142B1 (en) | 1991-04-10 | 2008-11-19 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| FR2734739B1 (fr) | 1995-06-01 | 1997-07-11 | Gec Alsthom Stein Ind | Dispositif de surveillance d'un broyeur a boulets |
| TW311927B (OSRAM) | 1995-07-11 | 1997-08-01 | Minnesota Mining & Mfg | |
| EP0795743A3 (en) | 1996-03-15 | 1998-02-25 | Japan Tobacco Inc. | Method and apparatus for infra-red moisture measurement |
| US5839430A (en) | 1996-04-26 | 1998-11-24 | Cama; Joseph | Combination inhaler and peak flow rate meter |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| US6358058B1 (en) | 1998-01-30 | 2002-03-19 | 1263152 Ontario Inc. | Aerosol dispensing inhaler training device |
| AU775076B2 (en) | 1998-12-10 | 2004-07-15 | Bristol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| KR100857943B1 (ko) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
| DK1390535T3 (da) | 2001-04-26 | 2010-12-06 | Amgen Mountain View Inc | Kombinatoriske biblioteker af monomer-domæner |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| ATE556591T1 (de) | 2001-11-08 | 2012-05-15 | Abbott Biotherapeutics Corp | Stabile pharmazeutische flüssigformulierung von igg-antikörpern |
| AU2003234439A1 (en) | 2002-05-07 | 2003-11-11 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
| AU2003290682A1 (en) * | 2002-11-15 | 2004-06-15 | Centocor, Inc. | Anti-angiogenic uses of il-6 antagonists |
| WO2005062955A2 (en) | 2003-12-23 | 2005-07-14 | Rinat Neuroscience Corp. | Agonist anti-trkc antibodies and methods using same |
| DK2213683T3 (da) | 2004-08-04 | 2013-09-02 | Mentrik Biotech Llc | VARIANT-Fc-REGIONER |
| EP1789446A2 (en) | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| BRPI0620797A2 (pt) | 2005-12-30 | 2011-11-22 | Merck Patent Ges Mit Beschonkter Haftung | anticorpos anti-il-6 que previnem a ligação de il-6 complexado com il-6ralfa a gp130 |
| EP2004690A2 (en) | 2006-03-13 | 2008-12-24 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| AU2007307324B2 (en) | 2006-05-19 | 2013-08-15 | Alder Biopharmaceuticals, Inc. | Culture method for obtaining a clonal population of antigen-specific B cells |
| TWI617576B (zh) * | 2007-05-21 | 2018-03-11 | 艾爾德生物控股有限責任公司 | 介白素-６（ｉｌ-６）的抗體及其等之用途 |
| CN101855336B (zh) | 2007-09-14 | 2019-07-30 | 赛诺菲巴斯德生物制剂有限责任公司 | 含艰难梭菌类毒素a和b的药物组合物 |
| CA2705879A1 (en) | 2007-11-21 | 2009-06-04 | Amgen Inc. | Wise binding agents and epitopes |
| US20100187601A1 (en) | 2007-12-12 | 2010-07-29 | Fujio Masuoka | Semiconductor device |
| SG2013054218A (en) | 2008-01-15 | 2014-10-30 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
| BRPI0916668B1 (pt) | 2008-08-05 | 2021-12-28 | Novartis Ag | Anticorpo monoclonal isolado, composição farmacêutica, ácido nucleico isolado e vetor |
| DK2324930T3 (da) | 2008-09-12 | 2012-12-10 | Kdf Co Ltd | Vandsprøjteindretning |
| US20120005773A1 (en) | 2008-10-01 | 2012-01-05 | Aasen Eric D | Transgenic plants with enhanced agronomic traits |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| CN102224169A (zh) | 2008-11-26 | 2011-10-19 | 葛兰素集团有限公司 | 多肽、抗体可变结构域和拮抗剂 |
| WO2010088444A1 (en) | 2009-01-29 | 2010-08-05 | Medimmune, Llc | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| PE20130643A1 (es) | 2010-07-12 | 2013-06-07 | Covx Technologies Ireland Ltd | Conjugados de anticuerpos multifuncionales |
| PE20150361A1 (es) | 2012-07-13 | 2015-03-14 | Roche Glycart Ag | Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares |
| AU2013334740A1 (en) | 2012-10-25 | 2015-04-02 | Medimmune, Llc | Stable, low viscosity antibody formulation |
| RU2670943C9 (ru) * | 2012-11-08 | 2018-11-26 | Илэвэн Байотерапьютикс, Инк. | Антагонисты ил-6 и их применение |
| EP3019243A4 (en) | 2013-07-12 | 2017-03-15 | Ophthotech Corporation | Methods for treating or preventing ophthalmological conditions |
| WO2016073894A1 (en) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
-
2015
- 2015-11-06 MY MYPI2017000609A patent/MY185114A/en unknown
- 2015-11-06 EP EP19189890.7A patent/EP3632931A1/en active Pending
- 2015-11-06 EA EA201791005A patent/EA035199B1/ru not_active IP Right Cessation
- 2015-11-06 HR HRP20251312TT patent/HRP20251312T1/hr unknown
- 2015-11-06 KR KR1020247004699A patent/KR102770849B1/ko active Active
- 2015-11-06 EP EP23189385.0A patent/EP4268843B1/en active Active
- 2015-11-06 RS RS20251073A patent/RS67353B1/sr unknown
- 2015-11-06 EP EP15797538.4A patent/EP3215530B9/en active Active
- 2015-11-06 JP JP2017543332A patent/JP6594438B2/ja active Active
- 2015-11-06 ES ES15797538T patent/ES2756275T3/es active Active
- 2015-11-06 RS RS20191447A patent/RS59805B1/sr unknown
- 2015-11-06 US US15/524,727 patent/US11142571B2/en active Active
- 2015-11-06 SG SG11201703574VA patent/SG11201703574VA/en unknown
- 2015-11-06 CR CR20170231A patent/CR20170231A/es unknown
- 2015-11-06 WO PCT/US2015/059532 patent/WO2016073890A1/en not_active Ceased
- 2015-11-06 PH PH1/2017/500809A patent/PH12017500809B1/en unknown
- 2015-11-06 MX MX2017005992A patent/MX385206B/es unknown
- 2015-11-06 PT PT157975384T patent/PT3215530T/pt unknown
- 2015-11-06 SG SG10202103420PA patent/SG10202103420PA/en unknown
- 2015-11-06 MA MA051554A patent/MA51554A/fr unknown
- 2015-11-06 HR HRP20191945TT patent/HRP20191945T1/hr unknown
- 2015-11-06 IL IL251858A patent/IL251858B/en unknown
- 2015-11-06 LT LTEP23189385.0T patent/LT4268843T/lt unknown
- 2015-11-06 SI SI201530995T patent/SI3215530T1/sl unknown
- 2015-11-06 DK DK15797538T patent/DK3215530T3/da active
- 2015-11-06 UA UAA201705592A patent/UA122673C2/uk unknown
- 2015-11-06 PT PT231893850T patent/PT4268843T/pt unknown
- 2015-11-06 HU HUE15797538A patent/HUE046181T2/hu unknown
- 2015-11-06 DK DK23189385.0T patent/DK4268843T3/da active
- 2015-11-06 KR KR1020177014412A patent/KR102636726B1/ko active Active
- 2015-11-06 PE PE2017000804A patent/PE20171107A1/es unknown
- 2015-11-06 CN CN201580065652.6A patent/CN107249631B/zh active Active
- 2015-11-06 PL PL15797538T patent/PL3215530T3/pl unknown
- 2015-11-06 PL PL23189385.0T patent/PL4268843T3/pl unknown
- 2015-11-06 FI FIEP23189385.0T patent/FI4268843T3/fi active
- 2015-11-06 AU AU2015342882A patent/AU2015342882B2/en active Active
- 2015-11-06 CA CA2965689A patent/CA2965689C/en active Active
-
2017
- 2017-04-28 ZA ZA201702985A patent/ZA201702985B/en unknown
- 2017-05-03 SA SA517381458A patent/SA517381458B1/ar unknown
- 2017-05-05 CL CL2017001135A patent/CL2017001135A1/es unknown
- 2017-05-08 MX MX2021008663A patent/MX2021008663A/es unknown
- 2017-05-30 CO CONC2017/0005404A patent/CO2017005404A2/es unknown
-
2021
- 2021-09-13 US US17/473,696 patent/US20220169719A1/en not_active Abandoned
-
2024
- 2024-05-13 US US18/662,445 patent/US20250059270A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20251312T1 (hr) | Poboljšana protutijela za il-6 | |
| JP2016504416A5 (OSRAM) | ||
| MY208416A (en) | Antibody capable of binding to thymic stromal lymphopoietin and use thereof | |
| HRP20210517T1 (hr) | Pripravci i postupci za protutijela usmjerena na epo | |
| AR076796A1 (es) | Proteinas de union al antigeno. composicion farmaceutica. uso. procedimiento. | |
| JP2017515811A5 (OSRAM) | ||
| CR20200099A (es) | Muteínas de interleucina 21 y métodos de tratamiento | |
| MX2022004786A (es) | Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular. | |
| HRP20211641T1 (hr) | Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti | |
| HRP20211794T1 (hr) | Humana antitijela za pd-1 | |
| RU2017119647A (ru) | Способ лечения болезней глаз | |
| HK1198446A1 (en) | Anti-vegf single variable domains fused to fc domains | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| PH12015501942A1 (en) | Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders | |
| AR102592A1 (es) | Anticuerpos biespecíficos y métodos de uso en oftalmología | |
| RU2009147744A (ru) | Профилактика и лечение патологических состояний глаз, вызванных комплементом | |
| JP2019510078A5 (OSRAM) | ||
| AR105938A1 (es) | Anticuerpo anti-epha4 | |
| JP2017535285A5 (OSRAM) | ||
| JP2018527327A5 (OSRAM) | ||
| HRP20220066T1 (hr) | Liječenje makularne degeneracije povezane sa starenjem s malom aktivnom koroidnom neovaskularizacijskom lezijom | |
| EA201100462A1 (ru) | Серосвязанные соединения для лечения офтальмологических заболеваний и расстройств | |
| JP2017502023A5 (OSRAM) | ||
| EA201890225A1 (ru) | Слитые белки, которые связываются с fc рецепторами человека | |
| JP2021507677A5 (OSRAM) |